Cowen reaffirmed their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research note issued to investors on Tuesday. Cowen currently has a $30.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on the stock. Cantor Fitzgerald reiterated a buy rating and set a $30.00 target price on shares of Dynavax Technologies in a research report on Monday, October 1st. BidaskClub downgraded shares of Dynavax Technologies from a sell rating to a strong sell rating in a research report on Saturday, August 18th. ValuEngine upgraded shares of Dynavax Technologies from a sell rating to a hold rating in a research report on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Dynavax Technologies from a sell rating to a hold rating in a research report on Thursday, August 9th. Finally, Royal Bank of Canada lifted their target price on shares of Dynavax Technologies to $26.00 and gave the stock an outperform rating in a research report on Monday, October 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Dynavax Technologies currently has a consensus rating of Hold and a consensus price target of $28.00.

NASDAQ:DVAX opened at $12.09 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87. Dynavax Technologies has a one year low of $9.63 and a one year high of $22.80. The company has a market cap of $756.69 million, a P/E ratio of -6.99 and a beta of 0.61.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative return on equity of 87.67% and a negative net margin of 5,044.85%. The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $3.16 million. During the same quarter in the prior year, the business earned ($0.38) earnings per share. The firm’s quarterly revenue was up 2822.0% on a year-over-year basis. On average, analysts expect that Dynavax Technologies will post -2.49 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Gofen & Glossberg LLC IL bought a new position in Dynavax Technologies during the 3rd quarter worth approximately $145,000. Tiverton Asset Management LLC bought a new position in Dynavax Technologies during the 2nd quarter worth approximately $184,000. WINTON GROUP Ltd bought a new position in Dynavax Technologies during the 1st quarter worth approximately $199,000. Xact Kapitalforvaltning AB bought a new position in Dynavax Technologies during the 1st quarter worth approximately $200,000. Finally, Bank of Montreal Can raised its holdings in Dynavax Technologies by 365.4% during the 2nd quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 10,943 shares during the last quarter. Hedge funds and other institutional investors own 81.48% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Read More: Trading Strategy Methods and Types

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.